🧬 One amino acid to stabilize them all — myth or molecular reality?
🔗 Single-residue engineering of lambda (λ) antibody light chains reduces conformational flexibility and enhances thermal stability. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.10.045
đź“š CSBJ: https://www.csbj.org/
#MonoclonalAntibodies #mAbs #Immunology #ComputationalBiology #MolecularDynamics #Bioinformatics #ProteinStability #StructuralBiology
Conjugates of Biofabricated Ag2S Quantum Dots with Monoclonal Antibodies for Microtubule Visualization - #Ag2S #quantumdots #functionalization #monoclonalantibodies #bioconjugation #spectrophotometry #microtubules #MicrotubuleVisualization - https://link.springer.com/article/10.3103/S0095452725040036
🔬 Can AI help decode how antibodies recognize cancer-related proteins like HER2?
đź”— Investigating and evaluating potential antigen binding sites for monoclonal anti-HER2 antibodies: The LightDock approach. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.06.001
đź“š CSBJ: https://www.csbj.org/
#HER2 #CancerResearch #MonoclonalAntibodies #LightDock #AlphaFold #Bioinformatics #MolecularDocking #InSilicoBiology #ComputationalBiology #AntibodyResearch #StructuralBiology
Hidden Ivermectin Data - Dr Mary Talley on JRE
Africa: New Momentum for Monoclonal Antibodies Manufacturing in Africa: [Africa CDC] Created in the lab with ability to mimic natural antibodies--monoclonal antibodies, or mAbs, are one of the most promising medical tools available today. http://newsfeed.facilit8.network/TKjDQN #MonoclonalAntibodies #AfricaHealth #InnovationInHealthcare #MedicalResearch #AntibodyTherapy
'Clinical trial underway to assess effectiveness and safety of potential Long Covid treatment'
"A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca's long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential treatment for Long Covid"
"The study will test whether the monoclonal antibody sipavibart, which is approved for the pre-exposure prophylaxis (prevention) of COVID-19 in Japan and the EU, is effective in treating Long Covid. The trial, which the FDA reviewed and cleared for the study earlier this year, is one of three Long Covid treatment trials expected to begin in 2025 that have been initiated and funded by SILC, a nonprofit organization founded in 2023 by philanthropists Eric and Wendy Schmidt to advance Long Covid care for patients globally."
"In 2024, researchers from the state published a study in the American Journal of Emergency Medicine detailing how a small group of these patients' Long COVID symptoms disappeared after they received the monoclonal antibodies to prevent or treat acute episodes of the virus."
"double-blind, randomized and controlled trial"
@longcovid
#health #LongCovid #sipavibart #MonoclonalAntibodies
🔬 Antibodies.com offers 5,000+ recombinant monoclonal antibodies - validated for WB, IHC, ELISA, FC, ChIP, Cryo-EM, and more.
👉 Explore our validated range: https://www.antibodies.com/primary-antibodies/recombinant-antibodies
#RecombinantAntibodies #MonoclonalAntibodies #AntibodyValidation
I am so happy for Emma♥️
She has been an amazing advocate for ppl with #longcovid in #Sweden while her own health has just declined...
I hope that this can be a turnaround for her and a breakthrough in general!🙏♥️
#monoclonalantibodies
#kavigale
#longcovid
#pots
#postcovid
#karolinska
#Stockholm
RE: https://bsky.app/profile/did:plc:r3q4um3kwgnrd2hywmexkkyg/post/3lmwfu4xto22p
For my fellow allergy sufferers - this looks promising!
> That means an injection could stop all allergic reactions — not only seasonal allergies but food allergies (such as peanuts) and insect allergies for a prolonged period of time.
https://www.vox.com/health/408749/allergy-season-pollen-grass-cure-treatment
via @Vox
Structural Convergence and Water-Mediated Substrate Mimicry Enable Broad #Neuraminidase #Inhibition by #Human #Antibodies
Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.11.27.625426v1?rss=1
Abstract
Influenza has been responsible for multiple global pandemics and seasonal epidemics and claimed millions of lives. The imminent threat of a panzootic outbreak of avian influenza H5N1 virus underscores the urgent need for pandemic preparedness and effective countermeasures, including monoclonal antibodies (mAbs). Here, we characterize human mAbs that target the highly conserved catalytic site of viral neuraminidase (NA), termed NCS mAbs, and the molecular basis of their broad specificity. Cross-reactive NA-specific B cells were isolated by using stabilized NA probes of non-circulating subtypes. We found that NCS mAbs recognized multiple NAs of influenza A as well as influenza B NAs and conferred prophylactic protections in mice against H1N1, H5N1, and influenza B viruses. Cryo-electron microscopy structures of two NCS mAbs revealed that they rely on structural mimicry of sialic acid, the substrate of NA, by coordinating not only amino acid side chains but also water molecules, enabling inhibition of NA activity across multiple influenza A and B viruses, including avian influenza H5N1 clade 2.3.4.4b viruses. Our results provide a molecular basis for the broad reactivity and inhibitory activity of NCS mAbs targeting the catalytic site of NA through substrate mimicry.
____
#aH1n1 #aH5n1 #abstract #avianInfluenza #AVIANINFLUENZA #birdFlu #h5n1 #health #influenzaB #monoclonalAntibodies #news #research #SEASONALINFLUENZA
Structural basis of broad #protection against #influenza virus by a #human #antibody targeting the #neuraminidase active site via a recurring motif in CDR H3
Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.11.26.625467v1
Abstract
Influenza viruses evolve rapidly, driving seasonal epidemics and posing global pandemic threats. While neuraminidase (NA) has emerged as a vaccine target, shared molecular features of NA antibody responses are still not well understood. Here, we describe cryo-electron microscopy structures of the broadly protective human antibody DA03E17, which was previously identified from an H1N1-infected donor, in complex with NA from A/H1N1, A/H3N2, and B/Victoria-lineage viruses. DA03E17 targets the highly conserved NA active site using its long CDR H3, which features a DR (Asp-Arg) motif that engages catalytic residues and mimics sialic acid interactions. We further demonstrate that this motif is conserved among several NA active site-targeting antibodies, indicating a common receptor mimicry strategy. We also identified potential antibody precursors containing this DR motif in all donors of a healthy human donor BCR database, highlighting the prevalence of this motif and its potential as vaccine targeting. Our findings reveal shared molecular features in NA active site-targeting antibodies, offering insights for NA-based universal influenza vaccine design.
____
#aH3n2 #abstract #biology #h1n1pdm09 #health #immunology #influenzaA #monoclonalAntibodies #research #vaccine
Protective threshold of a potent neutralizing #Zika virus monoclonal #antibody in rhesus #macaques
Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01429-24?af=R
ABSTRACT
Zika virus (ZIKV) is a mosquito-borne flavivirus that caused a global pandemic in 2016–2017 with continued ongoing transmission at low levels in several countries. In the absence of an approved ZIKV vaccine, neutralizing monoclonal antibodies (mAbs) provide an option for the prevention and treatment of ZIKV infection. Previous studies identified a potent neutralizing human mAb ZIKV-117 that reduced fetal infection and death in mice following ZIKV challenge. In this study, we report exquisite potency of ZIKV-117-LALA-YTE, which has been engineered to reduce Fc receptor binding and to extend half-life, in a titration study in rhesus macaques to protect against ZIKV challenge. We show complete protection at a dose of 0.016 mg/kg ZIKV-117-LALA-YTE, which resulted in median serum concentrations of 0.13 µg/mL. The high potency of this mAb supports its potential clinical development as a novel biotherapeutic intervention for ZIKV.
____
#abstract #animalModels #monoclonalAntibodies #research #zikaVirus
Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2024.11.08.622746v1?rss=1
Abstract
Pemivibart (Pemgarda/VYD222) was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on March 22, 2024, for COVID-19 pre-exposure prophylaxis in immunocompromised individuals. However, its efficacy and resistance against JN.1 sublineages have yet to be fully characterized. Here, we first assessed the neutralizing activity of Pemivibart against a panel of VSV-based pseudoviruses representing contemporary JN.1 sublineages, including XEC, the fastest-growing SARS-CoV-2 strain globally, in both Vero-E6 and Vero-E6-TMPRSS2-T2A-hACE2 (Vero-E6-TA) cells. We then engineered a replication-competent vesicular stomatitis virus with JN.1 spike (rVSVΔG-JN.1) to select for escape variants and performed structural analyses to comprehensively map Pemivibart’s escape mutations. Our results demonstrated that Pemivibart exhibited comparable neutralization patterns in both cell lines and retains broad effectiveness against SARS-CoV-2 JN.1 sublineages tested. However, its potency was remarkably reduced against KP.3.1.1 and XEC, with IC50 values of approximately 4.2 μg/mL, about 22-fold higher than that for JN.1, as well as JN.1-derived Pemivibart-escape mutants harbouring low-frequency mutations across SARS-CoV-2 strains through mutiple antibody evasion mechanisms in Vero-E6-TA cells. Collectively, our findings underscored the importance of monitoring the clinical efficacy of Pemivibart as JN.1 sublineages continue to evolve. The escape profile of Pemivibart could provide valuable insights for forecasting and optimizing its effectiveness against emerging SARS-CoV-2 variants.
____
#abstract #covid #COVID19 #health #monoclonalAntibodies #research #sarsCov2 #vaccine
Source: Nature Communications, https://www.nature.com/articles/s41467-024-53301-6
Abstract
The influenza neuraminidase (NA) is a potential target for the development of a next-generation influenza vaccine, but its antigenicity is not well understood. Here, we isolate an anti-N6 human monoclonal antibody, named 18_14D, from an H5N6 avian influenza virus (AIV) infected patient. The antibody weakly inhibits enzymatic activity but confers protection in female mice, mainly via ADCC function. The cryo-EM structure shows that 18_14D binds to a unique epitope on the lateral surface of the N6 tetramer, preventing the formation of tightly closed NA tetramers. These findings contribute to the molecular understanding of protective immune responses to NA of AIVs in humans and open an avenue for the rational design of NA-based vaccines.
____
#aH5n6 #abstract #avianInfluenza #monoclonalAntibodies #research #vaccine
AbbVie puts potential $713M on the line for OSE’s inflammation antibody—Eli Lilly could launch obesity drug in India next year, CEO says—After steep cost cuts, Novavax's fourth-quarter performance falls short of expectations--http://bit.ly/w28kSd #abbvie #inflammation #monoclonalantibodies #earnings #novavax #india #elililly #obesity #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
A company formed by M.D. Anderson Cancer Center and Panacea Venture plans to develop synthetic antibodies as treatments addressing new cancer targets.
https://sciencebusiness.technewslit.com/?p=45176
#News #Press #Science #Business #Entrepreneurs #Biotechnology #StartUp #IntellectualProperty #Cancer #MonoclonalAntibodies #Tumors #Proteins #Antigens #Therapies #Treatments #VentureCapital
The developer of a biologic drug-making process with engineered plant crops is collaborating with a vertical farming company to create a network of biologics production facilities.
https://sciencebusiness.technewslit.com/?p=45058
#News #Press #Science #Business #Agriculture #Biotechnology #Collaboration #Biologics #MonoclonalAntibodies #Engineering #VerticalFarming #Tobacco #Automation #Algorithms #Italy #UK
Disease Modifying Therapy for #Alzheimer's #Dementia
"The long-awaited era of disease-modifying therapy for Alzheimer’s disease has finally arrived and will substantially impact how the disease is perceived and managed. The drugs closest to widespread clinical implementation are #lecanemab and #donanemab—intravenous #MonoclonalAntibodies that remove β #amyloid plaques from the #brain and can slow cognitive and functional decline."
#leqembi
https://cnmri.com/2023/07/21/disease-modifying-therapy-for-alzheimers/
My latest Clinical Pipeline column for Nature Medicine: second generation anti-CD40L drugs for #MultipleSclerosis. A really cool story of deciphering the biology of adverse effects.
#Immunology #autoimmunedisease #drugdevelopment #monoclonalantibodies
Referenced link: https://medicalxpress.com/news/2023-06-monoclonal-antibodies-ace2-receptor-sars-cov-.html
Discuss on https://discu.eu/q/https://medicalxpress.com/news/2023-06-monoclonal-antibodies-ace2-receptor-sars-cov-.html
Originally posted by Phys.org / @physorg_com: http://nitter.platypush.tech/medical_xpress/status/1665708827449217029#m
RT by @physorg_com: New #monoclonalantibodies targeting ACE2 receptor could treat the next waves of SARS-CoV-2 @NatureMicrobiol https://www.nature.com/articles/s41564-023-01389-9 https://medicalxpress.com/news/2023-06-monoclonal-antibodies-ace2-receptor-sars-cov-.html
